Voyageur Pharmaceuticals Stock Fundamentals
| VM Stock | CAD 0.05 0.01 9.09% |
Voyageur Pharmaceuticals fundamentals help investors to digest information that contributes to Voyageur Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Voyageur Stock. The fundamental analysis module provides a way to measure Voyageur Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Voyageur Pharmaceuticals stock.
At this time, Voyageur Pharmaceuticals' Depreciation And Amortization is fairly stable compared to the past year. Reconciled Depreciation is likely to climb to 3,794 in 2024, whereas Other Operating Expenses is likely to drop slightly above 779.8 K in 2024. Voyageur | Select Account or Indicator |
Voyageur Pharmaceuticals Company Return On Equity Analysis
Voyageur Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Voyageur Pharmaceuticals Return On Equity | -0.71 |
Most of Voyageur Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Voyageur Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Voyageur Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Voyageur Pharmaceuticals is extremely important. It helps to project a fair market value of Voyageur Stock properly, considering its historical fundamentals such as Return On Equity. Since Voyageur Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Voyageur Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Voyageur Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Voyageur Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Voyageur Pharmaceuticals has a Return On Equity of -0.71. This is 178.02% lower than that of the Pharmaceuticals sector and 247.92% lower than that of the Health Care industry. The return on equity for all Canada stocks is 129.03% higher than that of the company.
Voyageur Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Voyageur Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Voyageur Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Voyageur Pharmaceuticals competition to find correlations between indicators driving Voyageur Pharmaceuticals's intrinsic value. More Info.Voyageur Pharmaceuticals is rated first in return on equity category among related companies. It is rated first in return on asset category among related companies . At this time, Voyageur Pharmaceuticals' Return On Equity is fairly stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Voyageur Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Voyageur Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Voyageur Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Voyageur Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Voyageur Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Voyageur Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Voyageur Pharmaceuticals by comparing valuation metrics of similar companies.Voyageur Pharmaceuticals is currently under evaluation in return on equity category among related companies.
Voyageur Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Voyageur Pharmaceuticals from analyzing Voyageur Pharmaceuticals' financial statements. These drivers represent accounts that assess Voyageur Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Voyageur Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.8M | 8.5M | 7.5M | 5.2M | 4.7M | 4.1M | |
| Enterprise Value | 3.1M | 7.8M | 7.5M | 5.3M | 4.7M | 4.0M |
Voyageur Fundamentals
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 6.73 M | ||||
| Shares Outstanding | 138.81 M | ||||
| Shares Owned By Insiders | 10.21 % | ||||
| Number Of Shares Shorted | 9.54 K | ||||
| Price To Book | 6.28 X | ||||
| EBITDA | (1.34 M) | ||||
| Net Income | (1.4 M) | ||||
| Cash And Equivalents | 27.59 K | ||||
| Total Debt | 40 K | ||||
| Debt To Equity | 28.10 % | ||||
| Current Ratio | 0.16 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (991.25 K) | ||||
| Short Ratio | 1.26 X | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 0.55 | ||||
| Beta | 0.49 | ||||
| Market Capitalization | 6.94 M | ||||
| Total Asset | 2.16 M | ||||
| Retained Earnings | (9.13 M) | ||||
| Working Capital | (585.25 K) | ||||
| Net Asset | 2.16 M |
About Voyageur Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Voyageur Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Voyageur Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Voyageur Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 17.9 K | 15.9 K | |
| Total Revenue | 0.00 | 0.00 | |
| Cost Of Revenue | 2 K | 1.9 K | |
| Stock Based Compensation To Revenue | 0.00 | 0.00 | |
| Sales General And Administrative To Revenue | 0.00 | 0.00 | |
| Research And Ddevelopement To Revenue | 0.00 | 0.00 | |
| Capex To Revenue | 0.00 | 0.00 | |
| Revenue Per Share | 0.00 | 0.00 | |
| Ebit Per Revenue | 0.00 | 0.00 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyageur Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Voyageur Stock analysis
When running Voyageur Pharmaceuticals' price analysis, check to measure Voyageur Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyageur Pharmaceuticals is operating at the current time. Most of Voyageur Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Voyageur Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyageur Pharmaceuticals' price. Additionally, you may evaluate how the addition of Voyageur Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |